Interval debulking surgery for advanced epithelial ovarian cancer

Area of Science:

• Oncology
• Surgical Oncology
• Gynecologic Oncology

Background:

• Advanced epithelial ovarian cancer (stages III-IV) often requires treatment when primary debulking surgery is not feasible.
• Interval debulking surgery (IDS) is a potential treatment option following neoadjuvant chemotherapy.

Purpose of the Study:

• To evaluate the efficacy and complications of interval debulking surgery (IDS) in advanced epithelial ovarian cancer.
• To compare survival outcomes between IDS and conventional treatment (primary debulking surgery followed by adjuvant chemotherapy).

Main Methods:

• A systematic review and meta-analysis of randomized controlled trials (RCTs) were conducted.
• Searches included Cochrane Gynaecological Cancer Group Register, CENTRAL, MEDLINE, and EMBASE up to July 2009.
• Overall survival (OS) and progression-free survival (PFS) were analyzed using random-effects models.

Main Results:

• Three RCTs involving 853 women were included. No significant difference in OS or PFS was found between IDS and chemotherapy alone.
• Subgroup analysis indicated a potential OS benefit for IDS in patients with less extensive primary surgery (HR=0.68, 95% CI 0.53-0.87).
• Chemotherapy toxicity rates were similar; data on other adverse events and quality of life were limited.

Conclusions:

• Current evidence is inconclusive regarding the survival benefits of IDS in advanced ovarian cancer compared to conventional treatment.
• IDS may offer a survival advantage in specific patient subgroups, particularly when primary surgery is suboptimal.
• Further research is needed to clarify the role of IDS and its impact on quality of life and adverse events.